Sökning: id:"swepub:oai:DiVA.org:uu-80020" >
Orlistat in respond...
Orlistat in responding obese type 2 diabetic patients : meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland
-
Ruof, J (författare)
-
Golay, A (författare)
-
- Berne, Christian (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper
-
visa fler...
-
Collin, C (författare)
-
Lentz, J (författare)
-
Maetzel, A (författare)
-
visa färre...
-
(creator_code:org_t)
- 2005-03-01
- 2005
- Engelska.
-
Ingår i: International Journal of Obesity. - : Springer Science and Business Media LLC. - 0307-0565 .- 1476-5497. ; 29:5, s. 517-523
- Relaterad länk:
-
http://www.ncbi.nlm....
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- OBJECTIVE: The aim of this study is to review the clinical and economic rationale for the reimbursement of orlistat in responding obese patients with type 2 diabetes.METHODS: Data from seven randomized controlled clinical trials of orlistat in overweight and obese patients with type 2 diabetes were pooled. A subgroup analysis involving patients who achieved a response (defined as a weight loss of >/=5% after 12 weeks of treatment) was conducted. The outcomes of the pooled analysis were then used to construct a Markov health economic model covering an 11-y period. The incidences of diabetes-related micro- and macrovascular complications were derived from the United Kingdom Prospective Diabetes Study. The effects of changes in body mass index, and the impact of micro- and macrovascular complications on utilities were derived from published sources. Publicly available cost data were used and are presented here in 2001 Euros. Discounting of 3% was applied. A probabilistic sensitivity analysis was conducted to examine the robustness of results.RESULTS: A total of 1249 patients treated with orlistat and 1230 given placebo were eligible for the intent-to-treat analysis. At the end of the study period, 23% of orlistat patients achieved a weight reduction of >/=5%. These patients showed a mean decrease in HbA1C of 1.16%, a weight reduction of 8.6 kg, a reduction in total cholesterol of 5.3% and a reduction in systolic blood pressure of 5.2 mmHg. The base-case economic analysis revealed costs per quality-adjusted life year gained of euro14 000 in Sweden and euro13 600 in Switzerland.CONCLUSION: The data presented here support the utilization and reimbursement of orlistat in overweight and obese diabetic patients who respond to the treatment.
Nyckelord
- Anti-Obesity Agents/economics/*therapeutic use
- Blood Pressure/drug effects
- Cost-Benefit Analysis/methods
- Diabetes Mellitus; Type 2/*drug therapy/economics
- Hemoglobin A; Glycosylated/analysis
- Humans
- Insurance; Health; Reimbursement/economics
- Lactones/economics/*therapeutic use
- Obesity/*drug therapy
- Sweden
- Switzerland
- Treatment Outcome
- Weight Loss/drug effects
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas